摘要
目的:探讨ST段抬高型心肌梗死(STEMI)患者采用注射用重组人尿激酶原(rh Pro-UK)治疗的临床效果。方法:随机选取2014年1月至2015年12月,我院心血管内科确诊的符合纳入要求的120例STEMI患者进行研究,采用随机数字表法分为研究组和对照组各60例,研究组采用rh Pro-UK治疗,对照组采用尿激酶(UK)治疗,对比两组的溶栓治疗效果。结果:溶栓2h后,研究组回落≥50%、ST段完全回落率、再通率均显著的高于对照组患者,差异有统计学意义(P<0.05),研究组TIMI 2+3级率88.3%均显著的高于对照组患者的71.7%,差异有统计学意义(P<0.05);研究组治疗2h时刻的Fib测定值高于对照组患者(P<0.05);研究组的并发症率为8.3%显著低于对照组的21.7%,差异有统计学意义(P<0.05)。结论:STEMI患者采用注射用rh Pro-UK治疗安全可靠、效果较好、对患者纤溶系统的影响更小。
Objective： To investigate the clinical effect of ST segment elevation myocardial infarction （STEMI） patients treated with Recombinant Human Prourokinase for Injection （rhPro-UK）. Methods：Ran- domly selected from January 2014 to December 2014, our hospital cardiovascular internal medicine diagnosis of meet the requirements of the included 120 patients with STEMI, By using the random number table method were divided into study group and control group with 60 cases in each group, the study group using rhPro-UK treat- ment, the control group using urokinase （UK） therapy, thrombolytic treatment effects were compared between the two groups. Results：2h after thrombolysis, the study group fell more than 50% , the rate of complete ST segment, the recanalization rate was significantly higher than control group, the differences were statistically significant （P 〈 0. 05 ）, 2 ＋ 3 TIMI of the study group was 88.3% significantly higher than control group 71.7% , the difference was statistically significant （ P 〈 0.05 ） ; the study group 2H moment Fib was higher than that in control group （ P 〈 0.05 ） ; the study group complication rate was 8.3% lower than the control group 21.7%, the difference was statistically significant （ P 〈 0. 05 ）. Conclusion ： STEMI patients with injec- tion of rhPro-UK treatment is safe, reliable, effective, and the impact on the patient＇s fibrinolytic system is smaller.
出处
《心肺血管病杂志》
2017年第6期436-439,共4页
Journal of Cardiovascular and Pulmonary Diseases
关键词
ST段抬高型心肌梗死
重组人尿激酶原
尿激酶
溶栓
ST segment elevation myocardial infarction
Recombinant human Pro urokinase
Uroki-nase
Thrombolysis
作者简介
通信作者：彭绪东，副主任医师，研究方向：急诊。E-mail：pxd251@163．com
